Skip to main content

Table 3 Summary of pooled results

From: Neuromuscular blocking agents in acute respiratory distress syndrome: a systematic review and meta-analysis of randomized controlled trials

End point
(outcome)
Number of trials
(number of patients)
Number of events in each group (%) Resultsa Absolute effect per 1,000 treated patientsb Quality of evidence
Hospital mortality 3
(431)
Intervention: 76/223 (34%) RR, 0.72 (CI, 0.58 to 0.91); P = 0.005; I2 = 0 132 fewer per 1,000 (from 42 fewer to 198 fewer) Moderatec
   Control: 98/208 (47%)    
ICU mortality 3
(431)
Intervention: 70/223 (31.4%) RR, 0.70 (CI, 0.55 to 0.89); P = 0.004; I2 = 0 134 fewer per 1,000 (from 49 fewer to 201 fewer) Moderatec
   Control: 93/208 (44.7%)    
Mortality at 28 days 3
(431)
Intervention: 57/223 (25.6%) RR, 0.66 (CI, 0.50 to 0.87); P = 0.003; I2 = 0 132 fewer per 1,000 (from 51 fewer to 195 fewer) Moderatec
   Control: 81/208 (39%)    
Days free of mechanical ventilation at 28 days 3
(431)
n/a MD, 1.91 (CI, 0.28 to 3.55); P = 0.02; I2 = 0 n/a Moderatec
Duration of mechanical ventilation 3
(431)
n/a MD, 1.21 (CI, 4.23 to 1.81); P = 0.43; I2 = 0 n/a Moderatec
Barotrauma 3
(431)
Intervention: 9/223 (4%) RR, 0.43 (CI, 0.20 to 0.90); P = 0.02; I2 = 0 55 fewer per 1,000 (from 10 fewer to 77 fewer) Moderatec
   Control: 20/208 (9.6%)    
ICU Acquired weakness 3
(431)
Intervention: 73/223 (32.7%) RR, 1.08 (CI, 0.83 to 1.41); P = 0.57; I2 = 0 24 more per 1,000 (from 51 fewer to 122 more) Very weakcde
   Control: 62/208 (30%)    
ICU Length of stay 1
(339)
n/a MD, 1.80 (CI, 5.93 to 2.33); P = 0.39 n/a n/a
  1. CI, confidence interval; ICU, intensive care unit; MD, mean difference; n/a, not applicable; RR, risk ratio. aPooled relative risk among RCTs. bThe corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). cRated down for incomplete blinding. dRated down for ascertainment bias (limited assessment of weakness in two trials). eRated down for imprecision. GRADE, Working Group grades of evidence; High quality, further research is very unlikely to change our confidence in the estimate of effect; Moderate quality, further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate; low quality, Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate; very low quality, we are very uncertain about the estimate.